• Access to Quality Assured and Affordable Asthma Medicines for the Working Poor in Kenya

Problem Definition

  • Growing burden of non-communicable diseases (NCDs) like asthma in Kenya; 10% of the population (4million) is estimated to be suffering from the condition
  • The working poor lack access to quality and affordable asthma medicines
    • Quality assured asthma relief medicines currently in the Kenyan market are not readily available in a form and pack sizes affordable to the working poor
  • GSK notably known for branded medicines typically serving middle and higher income earners in Kenya, launched a quick relieving asthma medicine to be dispensed using an inhaler to cater for the working poor market
  • Uptake of the medicine was low due to lack of an appropriate targeting and pro-poor marketing strategy

Business Model for Intervention

The solution, facilitated by DFID funding:

  • PSP4H is assisting GSK to improve access to quality assured and affordable asthma medicines for Kenya’s working poor using a double pronged approach:
    • a market research to understand the gaps and needs of working poor consumers, providers and retailers
    • developing a pro-poor specific marketing and distribution strategy for the asthma medicine to be piloted
  • GSK will build on the successful market roll-out of this asthmatic medicine for Kenya’s working poor as a platform to roll out other affordable asthma medicines to cater to this niche market group.
  • Glaxo SmithKline (Kenya) – British Multinational/Global Pharmaceutical and health consumer products company
  • GSK model for Africa including Kenya is to encourage access to medicines especially for neglected diseases and non-communicable diseases
  • Implementation of GSK’s marketing and distribution strategy with the improved understanding of the working poor consumer behaviour, will increase access to quality assured GSK asthma pro-poor medicine to an estimated 400,000 consumers in Kenya
  • Leverage on PSP4H’s established networks like KPA and TUNZA in pooled procurement to introduce product to their target consumers

Intervention Partner

  • Glaxo SmithKline (Kenya) – British Multinational/Global Pharmaceutical and health consumer products company
  • GSK model for Africa including Kenya is to encourage access to medicines especially for neglected diseases and non-communicable diseases

Expected Impact

  • Implementation of GSK’s marketing and distribution strategy with the improved understanding of the working poor consumer behaviour, will increase access to quality assured GSK asthma pro-poor medicine to an estimated 400,000 consumers in Kenya
  • Leverage on PSP4H’s established networks like KPA and TUNZA in pooled procurement to introduce product to their target consumers
Share